ANI launches generic Nilandron

BAUDETTE, Minn. — ANI Pharmaceuticals on Monday announced the immediate launch of its generic of Nilandron (nilutamide) tablets following the Food and Drug Administration’s approval of the drug. This is the first generic of the drug, which is indicated to treat metastatic prostate cancer in combination with surgical castration. 

 

Nilandron had trailing 12-month sales of $23 million according to IMS Health. 

 

“The nilutamide approval exemplifies ANI's strategic focus to introduce high barrier niche generic products,” ANI president Arthur Przybyl said. “We are excited to have secured approval for a first-to-market generic that represents ANI's second entry into the anti-cancer market and leverages our specialized high-potent manufacturing capability at our plant in Baudette, MN.”